Connexin mimetic peptide 40,37GAP26, a biologically active peptide, matches the GAP26 domain of the extracellular loop of major vascular connexins Cx37 and Cx40, referred to as 37,40Gap26 based on Cx homology. It has been utilized to examine gap junctions' involvement in propagating endothelial hyperpolarizations induced by cyclopiazonic acid (CPA) in the rodent iliac artery wall. Abundant gap junction plaques comprising Cx37 and Cx40 are present in the endothelium, and the peptide exerts inhibitory actions on subintimal hyperpolarization.

EPO Mimetic Peptide-1 (EMP-1) is a 20 amino acid peptide that promotes cell proliferation, modulates the cell cycle, and stimulates reticulocyte production in vivo [1].

Connexin mimetic peptide 40GAP27, corresponding to the GAP27 domain of the second extracellular loop of the dominant vascular connexin (Cx40), designated as 40Gap27, is a biologically active peptide utilized to study the pathways by which oxidant stress hinders gap junction communication. Administered 40Gap27 attenuates endothelium-dependent subintimal smooth muscle hyperpolarization.

Relamorelin (RM-131), a selective and potent growth hormone-releasing peptide/growth hormone secretagogue receptor (GHSR) agonist, is a potent growth hormone-releasing peptide mimetic with a high affinity for the GHS-1a receptor Relamorelin is a centrally permeable pentapeptide that increases growth hormone levels and accelerates gastric emptying and has potential for studying malignant disease.

Foxy-5 Ammonium Salt is a WNT5A agonist, a mimetic peptide of WNT5A, a non-classical member of the Wnt family.Foxy-5 Ammonium Salt triggers cytoplasmic free calcium signaling without affecting β-catenin activation and inhibits migration and invasion of epithelial cancer cells.Foxy-5 Foxy-5 Ammonium Salt effectively reduces the metastatic spread of prostate cancer cells with low WNT5A expression in an in situ mouse model.

Gap 26 is a mimetic peptide corresponding to the residues 63-75 of connexin 43, which is a gap junction blocker.

G* Peptide, also denoted as LVGRQLEEFL (mouse), represents the amino acid sequence 113 to 122 ([113,122] apoJ) found in apolipoprotein J. This compound displays both anti-inflammatory and anti-atherogenic characteristics. When incorporated into an apoJ mimetic, it results in the formation of the HM-10/10 peptide, which functions as a novel chimeric high-density lipoprotein. The HM-10/10 peptide has been shown to confer protection to the retinal pigment epithelium (RPE) and photoreceptors against oxidant-induced cell death [1] [2].

Annexin/lipocortin 1-mimetic peptide; inhibits leukocyte extravasation. Reduces neutrophil adhesion and emigration, and promotes detachment of neutrophils from activated mesenteric endothelium in mice in vivo.

COG-1410 is an apolipoprotein E (apoE) peptide mimetic.

Ac2-12 TFA, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibits neutrophil extravasation and demonstrates antimigratory effects by attenuating the recruitment of neutrophils in experimental models of inflammation [1] [2].

G* peptide, also known as LVGRQLEEFL (mouse) TFA, is a segment corresponding to amino acids 113 to 122 ([113,122] apoJ) of apolipoprotein J. This compound possesses both anti-inflammatory and anti-atherogenic qualities. When combined with an apoJ mimetic, it constitutes the HM-10/10 peptide, a novel chimeric high-density lipoprotein mimetic peptide. The HM-10/10 peptide is notable for safeguarding retinal pigment epithelium (RPE) and photoreceptors from oxidant-induced cell death as referenced in sources [1] [2].

Foxy-5 is a wnt5a peptide mimetic

TAT-Gap19 TFA, a Cx mimetic peptide and specific connexin43 hemichannel (Cx43 HC) inhibitor, does not inhibit the corresponding Cx43 gap junction channels (GJCs). It crosses the blood-brain barrier and has been shown to alleviate liver fibrosis in mice [1] [2] [3].

S1H, a synthetic peptide mimetic of human growth hormone amino acids 36-51, acts as an antagonist to the growth hormone receptor. It forms an α-helical structure in solution and inhibits STAT5 phosphorylation triggered by human growth hormone in SK-MEL-28 and MALME-3M melanoma cell lines, as well as prolactin in IM-9 B cell lymphocytes, at concentrations of 100 and 200 nM.

Connexin43 mimetic peptide. Reduces swelling, astrogliosis, neuroinflammation and neuronal cell death following spinal cord injury ex vivo and in vivo. Exhibits analgesic effects in models of neuropathic pain. O'Carroll et al (2008) Connexin 43 mimetic peptides reduce swelling, astrogliosis and neuronal cell death after spinal cord injury. Cell.Commun.Adhes. 15 27 PMID:18649176 |Mao et al (2017) Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp.Brain.Res. 235 3033 PMID:28725925 |Kim et al (2017) Characterising the mode of action of extracellular Connexin43 channel mimetic peptides in an in vitro ischemia injury model. Biochem.Biophys.Acta. 1861 68 PMID:27816754 |Tonkin et al (2017) Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp.Neurol. 300 1 PMID:29055716

Peptide5 TFA, a connexin 43 mimetic peptide, mitigates swelling, astrogliosis, and neuronal cell death in animal models of spinal cord injury. Additionally, it suppresses the NLRP3 inflammasome, functioning as an anti-inflammatory agent [1] [2] [3].

Gap 26 TFA, a gap junction blocker, is a connexin mimetic peptide derived from the amino acid sequence 63-75 in the first extracellular loop of connexin 43, featuring the SHVR amino acid motif [1].